CELL INTELLIGENCE · 肿瘤细胞治疗研究

通过脂质辅助聚合物纳米颗粒工程化干扰素-γ增强型嵌合抗原受体巨噬细胞用于癌症免疫治疗

Engineering Interferon-γ-Enhanced Chimeric Antigen Receptor Macrophages via Lipid-Assisted Polymeric Nanoparticles for Cancer Immunotherapy.

目的 To develop an efficient strategy for in vivo engineering of M1-like CAR-Ms for cancer therapy. 方法 We designed a lentiviral vector encoding a CAR targeting BCMA and a cytokine cassette. Macrophages were transduced and

利用旁分泌 SIRPγ 衍生的 CD47 阻断剂增强抗 EGFRvIII CAR-T 细胞治疗对胶质母细胞瘤的疗效

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker.

嵌合抗原受体（CAR）T 细胞治疗胶质母细胞瘤（GBM）面临的一大挑战是其免疫抑制性微环境，其中密集分布着促肿瘤的胶质瘤相关小胶质细胞和巨噬细胞（GAM）。

CAR-T 疗法治疗中枢神经系统肿瘤的进展

Advances in CAR-T therapy for central nervous system tumors.

CAR-T 细胞疗法在中枢神经系统肿瘤中的应用已取得显著进展；

CAR-T 细胞疗法治疗胶质母细胞瘤：分子靶点与治疗策略的系统综述

CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.

纳入的研究于 2015 年至 2023 年间开展，共入组 151 例患者。

Bcl-2 修饰的嵌合抗原受体对增强实体瘤靶向的协同效应

Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting.

我们的研究结果表明，将抗凋亡分子整合到CART细胞中可能增强其对抗实体瘤的治疗效果。